Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) is closely linked to oxidative stress–induced mitochondrial dysfunction, disrupting the balance between fusion and fission processes and driving hepatic injury. Tirzepatide (TZP), a dual GLP-1/GIP receptor agonist, is recognized for its potent glycemic and weight-lowering effects, yet its influence on hepatic mitochondrial dynamics in diabetes remains unclear. In this study, diabetes was induced in Wistar rats using a high-fat diet and streptozotocin, followed by treatment with varying doses of TZP. Diabetic animals exhibited marked hyperglycemia, insulin resistance, elevated lipid peroxidation, reduced antioxidant capacity, and altered expression of mitochondrial fusion and fission markers, accompanied by significant hepatic inflammation and degeneration. TZP administration improved glycemic indices, restored redox balance, enhanced the expression of fusion-related genes (Mfn1, Mfn2, Opa1), and suppressed the expression of fission-related genes (Drp1, Fis1) in a dose-dependent manner. Medium and high doses notably preserved liver histoarchitecture and reduced inflammatory changes. These findings suggest that TZP mitigates T2DM-associated hepatic injury by favoring mitochondrial fusion, alleviating oxidative stress, and protecting tissue integrity. The results provide mechanistic insights into TZP’s hepatoprotective potential and highlight the need for further validation at protein and functional levels.
No takes yet. Share an insight, caveat, or question.
Fakhir et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: